SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DanZ who wrote (4233)2/4/2003 2:19:42 PM
From: Mike M  Read Replies (1) of 5582
 
Zicam continues to sell very well. File under "nosing" ahead of the competition.

biz.yahoo.com

<<Zicam Products Dominate 2002 Nasal Product Sales
Tuesday February 4, 8:02 am ET
Matrixx Initiatives' Zicam(R) Brand Cold Products Are Five of Top 10 Sellers in Q4


PHOENIX, Feb. 4 /PRNewswire-FirstCall/ -- Zicam® cold and allergy remedies are beating the competition -- cold.
Recent syndicated research drug sales data show sales of Zicam Cold Remedy nasal gel, Zicam Allergy Relief, Zicam Cold Remedy Swabs, Zicam Kids Size Cold Remedy Swabs, and Zicam Extreme Congestion Relief nosing ahead of competitive products. Manufactured by Matrixx Initiatives, Inc. (Nasdaq: MTXX - News), the products represented five of the top 10 items (SKUs) on a dollar sales per point of distribution basis among cold and allergy internal nasal products sold in drug stores during the last 12 weeks of 2002.

"The response from consumers this cold season has been amazing," said Carl J. Johnson, president and chief executive officer of Matrixx. "The cold and allergy categories are highly competitive. To accomplish these results against the larger brands reflects a tremendous acceptance from consumers and support from innovative retailers for the unique Zicam formulas."

The impressive sales performance underscores Matrixx's continued growth, and the success of the company's new product development strategy, which in 2002 focused on expanding the successful Zicam line of gel-based nasal products with the launch of five new items. The company currently markets seven SKUs of Zicam products, which are widely available at food, drug and mass merchandise stores throughout the U.S.>>
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext